Listen to the New Episode of Lung Cancer Considered on the FDA Approval of Taletrectinib for ROS1-Positive NSCLC – IASLC

International Association for the Study of Lung Cancer shared a post on LinkedIn:

“The FDA has approved taletrectinib, a next-generation ROS1 inhibitor for NSCLC. But how does this new therapy compare with existing options—and where does it fit in the treatment landscape?

In this Lung Cancer Considered episode, Dr. Stephen Liu speaks with Dr. Enriqueta Felip and Dr. Jorge Nieva to break down the data behind the approval and discuss how clinicians can thoughtfully integrate taletrectinib into practice.

Listen now.”